Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is employed to improve muscle strength in myasthenia gravis and to reverse the effects of non‑depolarizing neuromuscular blocking agents in surgical settings. GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon belongs to the anticholinesterase drug class and is used where increased acetylcholine at the neuromuscular junction is required. - Myasthenia gravis: enhances skeletal‑muscle strength and reduces fatigue. - Reversal of neuromuscular blockade: restores normal neuromuscular transmission after surgery. - Ocular myasthenia: improves eye‑muscle function and reduces ptosis.

Mestinon may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased bowel movements. - Abdominal cramps: intermittent stomach pain. - Increased salivation: excess oral secretions. - Muscle cramps: involuntary muscle tightening. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Bradycardia: unusually slow heart rate. - Bronchospasm: narrowing of airway passages. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Cholinergic crisis: muscle weakness and respiratory difficulty. - Seizures: convulsive episodes in rare cases.

Before prescribing Mestinon, clinicians should consider several safety factors. - Dose adjustment in renal impairment: reduce dose as renal function declines. - Monitor for signs of cholinergic excess: watch for muscle twitching, sweating, or diarrhea. - Caution in patients with asthma or COPD: may exacerbate bronchospasm. - Avoid concomitant use with anticholinergic drugs: may diminish therapeutic effect. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at room temperature: keep in the original container, protect from moisture.

Mestinon can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Neostigmine: additive cholinergic effects may cause toxicity. - Beta‑blockers: may mask tachycardia that signals excess cholinergic activity. - Magnesium sulfate: potentiates neuromuscular blockade, increasing risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents (e.g., atropine): reduce Mestinon’s effectiveness. - Inhaled anesthetics (e.g., succinylcholine): may prolong neuromuscular blockade. - Diuretics: can affect electrolyte balance, influencing drug response.